Supriya Ghosh (Editor)

Aplaviroc

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Routes ofadministration
  
Oral

Legal status
  
Development terminated

PubChem CID
  
3001322

Molar mass
  
577.711 g/mol

ATC code
  
none

CAS Number
  
461023-63-2

IUPHAR/BPS
  
805

Aplaviroc

How to pronounce aplaviroc


Aplaviroc (INN, codenamed AK602 and GSK-873140) is a CCR5 entry inhibitor that belongs to a class of 2,5-diketopiperazines developed for the treatment of HIV infection. It was developed by GlaxoSmithKline.

In October 2005, all studies of aplaviroc were discontinued due to liver toxicity concerns. Some authors have claimed that evidence of poor efficacy may have contributed to termination of the drug's development; the ASCENT study, one of the discontinued trials, showed aplaviroc to be under-effective in many patients even at high concentrations.

References

Aplaviroc Wikipedia


Similar Topics